Transforming Medical Technology: The Launch of the Innovative Devices Access Pathway in the UK

By HEOR Staff Writer

September 20, 2023

A New Era of Medical Innovation

The Department of Health and Social Care (DHSC), Health Technology Wales (HTW), the Medicines and Healthcare products Regulatory Agency (MHRA), and several other health organizations have launched the Innovative Devices Access Pathway (IDAP) pilot. This new pathway, backed by £10 million of government funding, aims to fast-track patient access to innovative technologies by providing comprehensive support and advice to innovators and manufacturers.

A Pathway Paved with Potential

The IDAP is more than just a funding program. It’s a vision for the future of healthcare in the UK. The pathway aims to support the rapid development of innovative technologies that can be introduced into the National Health Service (NHS) to address unmet clinical needs. This is not just about getting new products to market quickly, but also ensuring they meet the highest standards of safety, quality, and effectiveness.

The pilot phase of the IDAP has now been launched, with innovators invited to submit Expressions of Interest for access into the pathway. Successful applicants will receive a range of support, including the development of a targeted product roadmap, system navigation advice, and support with Health Technology Assessments (HTA) for product realization and adoption.

The IDAP is open to both commercial and non-commercial innovators of medical technology in the UK and abroad. The submissions for the pilot phase opened on 19 September 2023 and will close on 29 October 2023. The future of healthcare is here, and it’s innovative, inclusive, and incredibly exciting.

Reference url

Recent Posts

Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurement Challenges

By João L. Carapinha

October 30, 2025

African Pharmaceutical Growth remains stifled by significant barriers, as highlighted in a recent plenary address at the Conference on Public Health in Africa (CPHIA) 2025 (reported by Health Policy Watch). Dr. Stavros Nicolaou, group senior executive for strategic trade at Aspen Pharmacare and c...
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health

By João L. Carapinha

October 28, 2025

A BMJ article explores the potential for AI chatbot delusions to validate or induce delusional thinking. Emerging evidence shows that individuals with and without previous psychiatric histories have reported distressing delusions after extensive chatbot interactions. It remains uncertain if AI di...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex Dynamics

By João L. Carapinha

October 27, 2025

Pharmaceutical innovation funding in the UK faces scrutiny amid industry claims that low NHS spending deters investments, but this narrative overlooks key drivers like scientific talent, tax incentives, and operational efficiencies rather than drug prices alone. A recent Lancet article critiques ...